Even in comparison to its direct obesity/ diabetic issues therapy pharmaceutical peer, LLY at FWD P/E valuations of fifty eight.71x Using the projected adj EPS expansion in a CAGR of +sixty five.four% through FY2026, it https://laytndayc086335.bluxeblog.com/61348027/5-simple-statements-about-where-to-find-wegovy-in-stock-explained